Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.

被引：0

作者：

Drilon, Alexander E.

Kummar, Shivaani

Lin, Jessica Jiyeong

Tan, Daniel Shao-Weng

Moreno, Victor

Leyvraz, Serge

Dubashi, Biswajit

Haresh, K. P.

Burcoveanu, Domnita-Ileana

Neu, Natascha

Mussi, Chiara E.

Shen, Lin

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Oregon Hlth & Sci Univ, Portland, OR USA

[4] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[5] Harvard Med Sch, Boston, MA USA

[6] Duke NUS Med Sch, Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[7] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain

[8] Charit Univ Med Berlin, Berlin, Germany

[9] Jawaharlal Inst Postgrade Med Educ & Res, Pondicherry, India

[10] All India Inst Med Sci AIIMS, New Delhi, India

[11] Bayer HealthCare Pharmaceut Inc, Basel, Switzerland

[12] Chrestos Concept GmbH & Co KG, Essen, Germany

[13] Bayer SpA, Milan, Italy

[14] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing Key Lab Carcinogenesis & Translat Res, State Key Lab Holist Integrat Management Gastroin, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8570

引用

页数：1

共 50 条

[1] Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Patel, Jyoti D.
Rosen, Lee S.
Solomon, Benjamin Maurice
Norenberg, Ricarda
Dima, Laura
Brega, Nicoletta
Shen, Lin
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
Hong, David S.
Shen, Lin
van Tilburg, Cornelis Martinus
Tan, Daniel Shao-Weng
Kummar, Shivaani
Lin, Jessica Jiyeong
Doz, Francois P.
McDermott, Raymond S.
Albert, Catherine M.
Berlin, Jordan
Bielack, Stefan S.
Lassen, Ulrik Niels
Tahara, Makoto
Norenberg, Ricarda
Shurshalina, Anna
Fellous, Marc Mardoche
Nogai, Hendrik
Xu, Rui-hua
Laetsch, Theodore Willis
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Lin, Jessica Jiyeong
Tan, Daniel Shao-Weng
Kummar, Shivaani
Patel, Jyoti D.
Cermignani, Luciano
Dai, Ming-Shen
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Rosen, Lee S.
Saada-Bouzid, Esma
Solomon, Benjamin Maurice
Xu, Rui-Hua
Yachnin, Jeffrey
Norenberg, Ricarda
Burcoveanu, Domnita-Ileana
Mussi, Chiara E.
Shen, Lin
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Rieke, D. T.
Lin, Iyeong J.
Tan, D. S.
Kummar, S.
Patel, J. D.
Cermignani, L.
Dai, M. -S.
Lassen, U. N.
Leyvraz, S.
Liu, Y.
Moreno, V.
Rosen, L.
Saada-Bouzid, E.
Solomon, B.
Xu, R. -H.
Yachnin, J.
Norenberg, R.
Burcoveanu, D. -I.
Mussi, C. E.
Shen, L.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 9 - 10
[5] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer
Leyvraz, S.
Hong, D. S.
Shen, L.
van Tilburg, C. M.
Tan, D. S. W.
Kummar, S.
Lin, J. J.
Doz, F.
McDermott, R.
Albert, C. M.
Berlin, J.
Bielack, S.
Lassen, U. N.
Tahara, M.
Norenberg, R.
Shurshalina, A.
Fellous, M.
Nogai, H.
Xu, R.
Laetsch, T. W.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 13 - 13
[6] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
Hong, David S.
Drilon, Alexander E.
Tan, Daniel Shao-Weng
Lin, Jessica Jiyeong
Kummar, Shivaani
McDermott, Raymond S.
Berlin, Jordan
Italiano, Antoine
Lassen, Ulrik Niels
Leyvraz, Serge
Tahara, Makoto
Norenberg, Ricarda
Burcoveanu, Domnita-Ileana
Brega, Nicoletta
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
Drilon, Alexander E.
Hong, David S.
Van Tilburg, Cornelis Martinus
Doz, Francois
Tan, Daniel S. W.
Kummar, Shivaani
Lin, Jessica Jiyeong
McDermott, Raymond S.
Zwaan, C. Michel
Norenberg, Ricarda
Fellous, Marc Mardoche
Brega, Nicoletta
Xu, Rui-Hua
Laetsch, Theodore Willis
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
Moreno Garcia, V.
Lin, J.
Patel, J.
Lassen, U.
Solomon, B.
Rosen, L.
Leyvraz, S.
Tan, D. S. W.
Reeves, J. A.
Beckmann, G.
Rudolph, M.
Wierzbinska, J.
Dima, L.
Brega, N.
Kummar, S.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S786 - S787
[9] Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Drilon, Alexander E.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Patel, Jyoti D.
Lassen, Ulrik Niels
Leyvraz, Serge
Moreno, Victor
Rosen, Lee S.
Solomon, Benjamin Maurice
Yachnin, Jeffrey
Liu, Yongmei
Dai, Ming-Shen
Norenberg, Ricarda
Fellous, Marc Mardoche
Mussi, Chiara Erminia
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
Rieke, D. T.
Hong, D. S.
Drilon, A.
Tan, D. S.
Lin, J.
Kummar, S.
McDermott, R.
Berlin, J.
Italiano, A.
Lassen, U. N.
Leyvraz, S.
Tahara, M.
Norenberg, R.
Burcoveanu, D. -I.
Brega, N.
Shen, L.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 142 - 143

← 1 2 3 4 5 →